Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
The closing price of HCA Healthcare Inc (NYSE: HCA) was $486.77 for the day, down -2.71% from the previous closing price of $500.31. In other words, the price has decreased by -$2.71 from its previous closing price. On the day, 1.88 million shares were traded. HCA stock price reached its highest trading level at $501.74 during the session, while it also had its lowest trading level at $485.45.
Ratios:
Our analysis of HCA’s different ratios will help us gain a deeper understanding of the company. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 101.81 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 13.72. For the most recent quarter (mrq), Quick Ratio is recorded 0.76 and its Current Ratio is at 0.85.
BofA Securities Downgraded its Buy to Neutral on July 16, 2025, while the target price for the stock was maintained at $394.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Nov 05 ’25 when McAlevey Michael R sold 3,892 shares for $473.79 per share. The transaction valued at 1,843,991 led to the insider holds 3,487 shares of the business.
Michael R McAlevey bought 3,892 shares of HCA for $1,843,991 on Nov 05 ’25. On Sep 08 ’25, another insider, Cuffe Michael S., who serves as the Officer of the company, bought 3,836 shares for $418.84 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, HCA now has a Market Capitalization of 113901019136 and an Enterprise Value of 159511937024. As of this moment, HCA’s Price-to-Earnings (P/E) ratio for their current fiscal year is 18.81, and their Forward P/E ratio for the next fiscal year is 16.33. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 1.28. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.49. Its current Enterprise Value per Revenue stands at 2.145 whereas that against EBITDA is 10.563.
Stock Price History:
The Beta on a monthly basis for HCA is 1.36, which has changed by 0.56322455 over the last 52 weeks, in comparison to a change of 0.12415576 over the same period for the S&P500. Over the past 52 weeks, HCA has reached a high of $520.00, while it has fallen to a 52-week low of $289.98. The 50-Day Moving Average of the stock is 6.94%, while the 200-Day Moving Average is calculated to be 26.01%.
Shares Statistics:
HCA traded an average of 1.34M shares per day over the past three months and 1378670 shares per day over the past ten days. A total of 229.85M shares are outstanding, with a floating share count of 158.13M. Insiders hold about 30.70% of the company’s shares, while institutions hold 62.80% stake in the company. Shares short for HCA as of 1763078400 were 4536300 with a Short Ratio of 3.39, compared to 1760486400 on 3263233. Therefore, it implies a Short% of Shares Outstanding of 4536300 and a Short% of Float of 2.8900001.
Dividends & Splits
With its trailing 12-month dividend rate of 2.82, HCA has a forward annual dividend rate of 2.82. Against a Trailing Annual Dividend Yield of 0.0056365053. The stock’s 5-year Average Dividend Yield is 0.75.
Earnings Estimates
As of right now, 20.0 analysts gave their recommendation on the stock of the company. The consensus estimate for the next quarter is $7.19, with high estimates of $7.6 and low estimates of $6.78.
Analysts are recommending an EPS of between $27.92 and $26.56 for the fiscal current year, implying an average EPS of $27.64. EPS for the following year is $29.75, with 22.0 analysts recommending between $31.42 and $27.77.
Revenue Estimates
It is expected that $90B in revenue will be generated in. The current quarter, according to 19 analysts. It ranges from a high estimate of $20.05B to a low estimate of $19.2B. As of. The current estimate, HCA Healthcare Inc’s year-ago sales were $18.29BFor the next quarter, 19 analysts are estimating revenue of $19.18B. There is a high estimate of $19.42B for the next quarter, whereas the lowest estimate is $18.61B.
A total of 22 analysts have provided revenue estimates for HCA’s current fiscal year. The highest revenue estimate was $76.14B, while the lowest revenue estimate was $74.48B, resulting in an average revenue estimate of $75.69B. In the same quarter a year ago, actual revenue was $70.6BBased on 21 analysts’ estimates, the company’s revenue will be $79.11B in the next fiscal year. The high estimate is $80.6B and the low estimate is $77B.
